The Lancet发表研究:HPV疫苗的接种在几十年内可能消除宫颈癌

2019-06-28 不详 MedSci原创

发表在"The Lancet"杂志上的一项最新研究发现,接种疫苗5到8年后,13至19岁女性HPV 16和18感染率显着下降了83%,20至24岁女性则显着下降了66%。

发表在"The Lancet"杂志上的一项最新研究发现,接种疫苗5到8年后,13至19岁女性HPV 16和18感染率显着下降了83%,20至24岁女性则显着下降了66%。

该研究一共涉及6000万人接种后8年的随访数据,显示出HPV疫苗接种对女性HPV感染和宫颈上皮内瘤变2+(CIN2),以及对男性和女性肛门生殖器疣的影响。

不仅HPV病毒感染率下降,肛门生殖器疣在15至19岁女孩中显着下降67%,在20至24岁女性中下降54%,在25至29岁女性中显着下降31% 。男性也受益,在15至19岁的男孩中,肛门生殖器疣诊断显着下降了48%,而在20至24岁的男性中减少了32%。

来自加拿大拉瓦尔大学的Marc Brisson教授领导了这次审查,他告诉BBC:"如果可以实现和维持足够高的疫苗接种率,那么宫颈癌的消除(定义为每100000人中少于4例)在几十年内可能被实现。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1830132, encodeId=859018301324f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Aug 18 10:59:00 CST 2019, time=2019-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798816, encodeId=b2c11e9881623, content=<a href='/topic/show?id=d342e0516bd' target=_blank style='color:#2F92EE;'>#疫苗的接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70516, encryptionId=d342e0516bd, topicName=疫苗的接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ca5383, createdName=bbjsj_1979, createdTime=Fri May 08 21:59:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368644, encodeId=e1683686444e, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Sun Jun 30 06:56:53 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408200, encodeId=7af11408200c1, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Sun Jun 30 00:59:00 CST 2019, time=2019-06-30, status=1, ipAttribution=)]
    2019-08-18 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1830132, encodeId=859018301324f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Aug 18 10:59:00 CST 2019, time=2019-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798816, encodeId=b2c11e9881623, content=<a href='/topic/show?id=d342e0516bd' target=_blank style='color:#2F92EE;'>#疫苗的接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70516, encryptionId=d342e0516bd, topicName=疫苗的接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ca5383, createdName=bbjsj_1979, createdTime=Fri May 08 21:59:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368644, encodeId=e1683686444e, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Sun Jun 30 06:56:53 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408200, encodeId=7af11408200c1, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Sun Jun 30 00:59:00 CST 2019, time=2019-06-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1830132, encodeId=859018301324f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Aug 18 10:59:00 CST 2019, time=2019-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798816, encodeId=b2c11e9881623, content=<a href='/topic/show?id=d342e0516bd' target=_blank style='color:#2F92EE;'>#疫苗的接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70516, encryptionId=d342e0516bd, topicName=疫苗的接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ca5383, createdName=bbjsj_1979, createdTime=Fri May 08 21:59:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368644, encodeId=e1683686444e, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Sun Jun 30 06:56:53 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408200, encodeId=7af11408200c1, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Sun Jun 30 00:59:00 CST 2019, time=2019-06-30, status=1, ipAttribution=)]
    2019-06-30 thm112988

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1830132, encodeId=859018301324f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Aug 18 10:59:00 CST 2019, time=2019-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798816, encodeId=b2c11e9881623, content=<a href='/topic/show?id=d342e0516bd' target=_blank style='color:#2F92EE;'>#疫苗的接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70516, encryptionId=d342e0516bd, topicName=疫苗的接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ca5383, createdName=bbjsj_1979, createdTime=Fri May 08 21:59:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368644, encodeId=e1683686444e, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Sun Jun 30 06:56:53 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408200, encodeId=7af11408200c1, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Sun Jun 30 00:59:00 CST 2019, time=2019-06-30, status=1, ipAttribution=)]
    2019-06-30 一闲

相关资讯

《柳叶刀》主编:科研不是“精英文化”

“科研不是‘精英文化’,更不是少部分人的特权,而应该是大众化的。不管是教学医院还是普通医院,医生们都应该做科研,只不过侧重点有所不同。基层医生不一定要去做高精尖的研究,应该更多对平时的医疗工作进行评估与评价。”

柳叶刀公布了Kyowa Kirin公司CCR4单抗Poteligeo 治疗皮肤T细胞淋巴瘤的III期临床数据

"柳叶刀"杂志最近公布了Kyowa Hakko Kirin公司的Poteligeo药物 III期临床试验的数据,该试验进一步肯定其在美国获批用于治疗皮肤T细胞淋巴瘤(CTCL)。

中国医学科学院在《柳叶刀》发文 呼吁社会妥善保护双胞胎婴儿

中国医学科学院就据称世界首例基因编辑婴儿出生事件,代表中国医学科学界第一时间在国际权威医学杂志《柳叶刀》主动发声,撰文向全世界清晰表明中国医学界和科技界对此事件的立场、态度以及拟采取的积极措施,彰显了中国医学科技工作者严守伦理底线、扞卫人类尊严的决心与行动。此举对于减少因个别科技人员严重违反科学伦理和道德的行为可能对国家造成的负面影响,维护中国医学界和科技界形象有重要积极作用。

LANCET:重磅!柳叶刀发布:“预测心脏病突发”的新技术,有望拯救生命

心脏病发作一般都属突发性,如果能提前诊断势必会引导患者提前接受治疗并降低死亡率。近日,来自牛津大学等机构的研究人员合作开发了一种基于计算机断层扫描( CT )冠状动脉造影分析的新技术,可以在心脏病发作前几年就标记患者,并进行干预治疗。

Lancet Public Health:柳叶刀子刊:25年超过43万人研究:低碳水化合物饮食缩短寿命!

全球最权威的医学期刊《柳叶刀》子刊《柳叶刀公共卫生》(The Lancet Public Health)发表了一项研究,表明低碳水化合物饮食可以将预期寿命缩短长达4年。低碳水化合物饮食,它曾一度被认为有利于体重减轻,改善心脏代谢风险。但长达25年,超过43万人的研究表明:低碳水化合物饮食会缩减寿命。

开年大吉:张力教授领衔在《柳叶刀》杂志发表《中国抗肿瘤药物研发的挑战与改变:肿瘤学I期临床试验年度报告》

长期以来,冗长的药品审评流程导致很多新药在中国大陆迟迟无法上市,患者面临无药可用的困境,这一现象在业内被称为“药滞(Drug-lag)”。2017年以来,国家实施了一系列药品审评、监管制度改革,旨在彻底扭转这一困局。近年来,抗肿瘤药物研发模式也发生了巨大变革,“无缝(seamless)设计”逐渐取代传统的三阶段药物开发模式。I期临床试验从原来的安全性试验转变为机制验证性(proof-of-mech